A number of recent significant transactions in the South Korean biopharma space indicate some emerging trends as the sector develops and expands internationally. Scrip takes a look at the over-arching themes in M&A activity over the past few years and how these may differ from those being observed globally.

The now-Meridian subsidiary’s former CEO, COO and regulatory affairs director reportedly delayed telling the FDA and the public about incorrect results obtained from Magellan’s LeadCare line of blood tests.

During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.

Diagnostic kit maker Meridian Bioscience will be acquired by South Korean firms SD Biosensor and PE firm SJL Partners, accelerating entry into US market.